Recent studies [14,18] have suggested a plasma ENDO therapeutic threshold of 5.9 ng/mL, which results in improved treatment outcomes by reducing the risk of breast cancer recurrence by 30% [14]. The gene discussed is MANEA; the disease is breast carcinoma.